Results 91 to 100 of about 27,271 (263)

GlycoChat Uncovers Glycan–Lectin Circuits in the Tumor Microenvironment of Pancreatic Cancer

Advanced Science, EarlyView.
Aberrant glycosylation drives cancer progression, yet its role in the tumor microenvironment remains unclear. We developed GlycoChat to map glycan–lectin circuits at single‐cell resolution. We discovered that cancer cells induce immunosuppressive macrophage differentiation and impair phagocytosis through interactions with CLEC10A and SIGLEC3 ...
Dinh Xuan Tuan Anh, Sunanda Keisham, Arun Burramsetty, Lalhaba Oinam, Koichiro Kumano, Akihiro Kuno, Osamu Shimomura, Tatsuya Oda, Hiroaki Tateno   +8 more
wiley   +1 more source

Neoadjuvant sipuleucel-T induces both Th1 activation and immune regulation in localized prostate cancer. [PDF]

, 2019
Sipuleucel-T is the only FDA-approved immunotherapy for metastatic castration-resistant prostate cancer. The mechanism by which this treatment improves survival is not fully understood.
Chan, Stephen, Fong, Lawrence, Hagihara, Katsunobu, Oh, David Y, Simko, Jeffry, Wei, Xiao X, Zhang, Li   +6 more
core  

PRDM1+ Malignant Cells Mediate an Immunosuppressive Landscape and Resistance to Neoadjuvant Chemoradiotherapy and Immunotherapy in Esophageal Squamous Cell Carcinoma

Advanced Science, EarlyView.
Integrated scRNA‐seq, scTCR‐seq analysis, and functional assays identify PRDM1+ malignant epithelial cells with hyper lipid peroxidation characteristics that demonstrate reduced responsiveness to the nICRT treatment. Principal factor PRDM1 activates cysteine metabolism genes to modulate lipid peroxidation (an intrinsic cellular pathway related to ...
Dijian Shen, Rui Li, Yong She, Xuefei Liu, Yuanyang Huang, Yongling Ji, Keying Chen, Zhengbo Song, Runzhe Chen, Xuan Li, Qi Zhao, Qixun Chen, Ming Chen   +12 more
wiley   +1 more source

Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno

Lung Cancer: Targets and Therapy, 2023
Danielle Brazel,1 Sai-Hong Ignatius Ou,1,2 Misako Nagasaka1– 3 1Department of Medicine, University of California Irvine School of Medicine, Orange, CA, USA; 2Chao Family Comprehensive Cancer Center, Orange, CA, USA; 3St.
Brazel D, Ou SI, Nagasaka M
doaj  

Nitric oxide donors increase PVR/CD155 DNAM-1 ligand expression in multiple myeloma cells: role of DNA damage response activation [PDF]

, 2015
Background: DNAX accessory molecule-1 (DNAM-1) is an activating receptor constitutively expressed by macrophages/ dendritic cells and by T lymphocytes and Natural Killer (NK) cells, having an important role in anticancer responses; in this regard ...
ABRUZZESE, MARIA PIA, CIPPITELLI, Marco, FIONDA, Cinzia, MOLFETTA, Rosa, PAOLINI, Rossella, RICCI, BIANCAMARIA, SANTONI, Angela, SORIANI, Alessandra, ZINGONI, Alessandra   +8 more
core   +1 more source

Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy [PDF]

Clinical Cancer Research, 2016
AbstractThe receptors CD96 and TIGIT are expressed on the surface of T and natural killer (NK) cells, and recent studies suggest both play important inhibitory roles in immune function. CD96 has been shown to modulate immune cell activity in mice, with Cd96−/− mice displaying hypersensitive NK-cell responses to immune challenge and significant tumor ...
Blake, Stephen J., Dougall, William C., Miles, John J., Teng, Michele W.L., Smyth, Mark J.   +4 more
openaire   +3 more sources

Depletion of the RNA‐Editing Enzyme ADAR1 Invigorates the Antitumor Immunity of NK Cells

Advanced Science, EarlyView.
ADAR1 is upregulated in NK cells from melanoma patients, impairing their function. Its loss enhances NK cell tumor infiltration and cytotoxicity in vitro and in vivo. Mechanistically, ADAR1 deficiency destabilizes CD38 mRNA to reduce its expression, thereby increasing NK cell mobility and killing, which nominates it as a therapeutic target for NK cell ...
Shuhan Chen, Di Lu, Rukang Liang, Weikeng Tan, Erming Zhao, Sihuang Wu, Xintong Li, Yulong Song, Miaojian Wan, Xiaoyuan Xie, Qi Zhang, Qiuli Liu   +11 more
wiley   +1 more source

Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer

OncoImmunology, 2019
Immune checkpoints are intensively investigated as targets in cancer therapy. T-cell immunoreceptor with immunoglobulin (Ig) and ITIM domains (TIGIT) and its ligand poliovirus receptor (PVR) are recently emerging as novel promising targets in ...
Hauke Stamm, Leticia Oliveira-Ferrer, Eva-Maria Grossjohann, Jana Muschhammer, Vanessa Thaden, Franziska Brauneck, Roman Kischel, Volkmar Müller, Carsten Bokemeyer, Walter Fiedler, Jasmin Wellbrock   +10 more
doaj   +1 more source

Intrinsic Expression of Immune Checkpoint Molecule TIGIT Could Help Tumor Growth in vivo by Suppressing the Function of NK and CD8+ T Cells

Frontiers in Immunology, 2018
TIGIT, an immune checkpoint molecule widely expressed on NK cells, activated T cells and Tregs, has been involved in delivering inhibitory signals through the interaction with PVR.
Xiu-Man Zhou, Wan-Qiong Li, Ya-Hong Wu, Lu Han, Xin-Guang Cao, Xuan-Ming Yang, Hong-Fei Wang, Wen-Shan Zhao, Wen-Jie Zhai, Yuan-Ming Qi, Yan-Feng Gao   +10 more
doaj   +1 more source

Cytokine‐Engineered Chimeric Antigen Receptor‐T Cell Therapy: How to Balance the Efficacy and Toxicity

Advanced Science, EarlyView.
Cytokine‐engineered CAR‐T cells represent a promising immunotherapy against malignancies due to direct tumor killing and potent immunity response. However, significant toxicities, including CRS and ICANS, have restricted clinical applications. How to keep the risk‐benefit balance of the advanced therapy is of great importance for maximizing the benefit
Xinru Zhang, Gulizeba Aimaiti, Yuanye Guan, Yuzhe Sha, Wei Zhou, Jiefeng Shen, Bo Zhao, Wei‐En Yuan   +7 more
wiley   +1 more source